David E. Kleiner
0000-0003-3442-4453
Publication & Citation Trends
Publications
0 total
Combined treatment of durvalumab, bevacizumab and tremelimumab in subjects with hepatocellular carcinoma (HCC) or biliary tract carcinoma (BTC).
Cited by 0
Semantic Scholar
Altering the Gut Microbiome and Tumor Microenvironment in Advanced Liver Cancer: A Phase II Study of Nivolumab, Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers.
Cited by 2
Semantic Scholar
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial OA
Cited by 12
Semantic Scholar
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma OA
Cited by 6
Semantic Scholar
585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial OA
Cited by 0
Semantic Scholar
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles - correction
Cited by 0
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(371)
Hepatitis C virus research
(158)
Hepatitis B Virus Studies
(130)
Liver Disease and Transplantation
(101)
Drug-Induced Hepatotoxicity and Protection
(93)
Affiliations
Semmelweis University
Roche (Switzerland)
Tufts University
Atrium Health Wake Forest Baptist
Brigham and Women's Hospital